Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD93m

    Last close

    USD2.50

    ▲ 1.25 (100.00%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Volition Webinar: Unraveling the web of NETs in sepsis

Volition Webinar: Unraveling the web of NETs in sepsis

VolitionRx — 6 videos in collection

More on this equity

VolitionRX is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

In this webinar, intensive care specialist and haematology key opinion leader Dr Andrew Retter helps us understand the burden of sepsis and challenges in treatment and patient care, the connection between NETosis and sepsis, the future of tools and treatments, as well as the potential role of NETs in other disease areas, and the role of Volition’s diagnostics tools to address unmet need in the space.

Leading the panel and Q&A session is Soo Romanoff, Managing Director of Healthcare at Edison Group.

< Previous
Next >

You may also be interested in these:

Healthcare

VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II

Healthcare

VolitionRx webinar: Breakthrough liquid biopsy method for cancer detection

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free